Cytek Biosciences Inc Total Liabilities
Cytek Biosciences Inc total liabilities. Based on the latest financial reports, Cytek Biosciences Inc (CTKB) has total liabilities worth $121.47 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check CTKB financial resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Cytek Biosciences Inc (2019–2025)
Total liabilities of Cytek Biosciences Inc from 2019 to 2025. This chart illustrates how Cytek Biosciences Inc's total liabilities have evolved over time, based on quarterly financial data.
Cytek Biosciences Inc Competitors by Total Liabilities
The table below lists competitors of Cytek Biosciences Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Greenlam Industries Limited
NSE:GREENLAM
|
India | Rs-11.79 Billion |
|
IBEX Ltd
NASDAQ:IBEX
|
USA | $138.91 Million |
|
P10 Inc
NYSE:PX
|
USA | $506.42 Million |
|
Donegal Group A Inc
NASDAQ:DGICA
|
USA | $1.82 Billion |
|
Skjern Bank A/S
CO:SKJE
|
Denmark | Dkr13.79 Billion |
|
Kid ASA
OL:KID
|
Norway | Nkr3.19 Billion |
|
Shandong Fengyuan Chemical Co Ltd
SHE:002805
|
China | CN¥5.11 Billion |
|
Farglory FTZ Investment Holding Co Ltd
TW:5607
|
Taiwan | NT$16.67 Billion |
Liability Composition Analysis (2019–2025)
This chart breaks down Cytek Biosciences Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see balance sheet size of Cytek Biosciences Inc.
Liquidity & Leverage Metrics
Cytek Biosciences Inc Total Liabilities Ratios Explained
Cytek Biosciences Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.69 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.37 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.27 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Cytek Biosciences Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Cytek Biosciences Inc (2019–2025)
The table below shows the annual total liabilities of Cytek Biosciences Inc from 2019 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $119.80 Million | +15.46% |
| 2024-12-31 | $103.76 Million | +2.34% |
| 2023-12-31 | $101.39 Million | +7.95% |
| 2022-12-31 | $93.93 Million | +62.17% |
| 2021-12-31 | $57.92 Million | -75.46% |
| 2020-12-31 | $236.01 Million | +110.60% |
| 2019-12-31 | $112.06 Million | -- |
About Cytek Biosciences Inc
Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitate scientific advances in biomedical research and clinical applications. The company offers Cytek aurora, northern lights systems, and Cytek aurora evo systems delivers cell analysis; Cytek Aurora CS System, a cellular complexity to perform additional downstream genomic and proteomic studies usin… Read more